SCHEMBL5097580

SCHEMBL5097580

O=C1COc2cc(S(=O)(=O)n3ncc4ccc(N5CCNCC5)nc43)ccc2N1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.43
PKM P14618 1/20 0.38
POLB P06746 2/20 0.37
GAA P10253 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
TSHR P16473 1/20 0.37
KMT2A Q03164 2/20 0.36
CYP11B1 P15538 2/20 0.36
CYP11B2 P19099 2/20 0.36
DRD2 P14416 3/20 0.35
DRD4 P21917 3/20 0.35
DRD3 P35462 3/20 0.35
MEN1 O00255 1/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
THRB P10828 1/20 0.35
NR3C2 P08235 2/20 0.35
HTR6 P50406 1/20 0.34
HTR1A P08908 1/20 0.34
CHRM5 P08912 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5103528 0.90 LMNA (0.44) LMNAPKMPOLBGAARXFP1
SCHEMBL4555077 0.77 RXFP1 (0.50) PKMPOLBGAARXFP1KMT2A
SCHEMBL5097192 0.75 RXFP1 (0.45) LMNAPKMPOLBGAARXFP1
SCHEMBL5103784 0.74 LMNA (0.45) LMNAPKMPOLBGAARXFP1
SCHEMBL3343464 0.74 LMNA (0.43) LMNAPKMPOLBGAARXFP1
SCHEMBL5095031 0.73 HTR6 (0.47) LMNARXFP1KMT2ADRD2DRD4
SCHEMBL5091038 0.70 KHK (0.46) LMNARXFP1TSHRKMT2ADRD2
SCHEMBL19283931 0.69 DRD2 (0.40) KMT2ACYP11B1CYP11B2DRD2DRD4
SCHEMBL5097493 0.69 GBA1 (0.44) LMNAPKMPOLBCYP11B1CYP11B2
SCHEMBL3340984 0.69 HTR6 (0.47) LMNAPKMHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200471-A1 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2008-08-21 US claimed
US-20080200471-A1 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2008-08-21 US disclosed
US-20080200471-A1 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2008-08-21 US disclosed
US-20080200471-A1 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2008-08-21 US disclosed
WO-2008101247-A2 6 ' SUBSTITUTED INDOLE AND INDAZOLE DERIVATIVES HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200471-A1 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY HTR6, HTR1B, HTR1A LMNA 3575/4885PKM 3556/4885POLB 3775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.